Peptide Doping in Sport: What New Research Shows

The landscape of performance enhancement has shifted dramatically over the past decade. Where anabolic-androgenic steroids (AAS) once dominated conversations about doping, a new class of substances — peptides and peptide analogues — has quietly moved to the forefront. A critical review published in The Journal of Sports Medicine and Physical Fitness (Coutinho et al., 2026) takes a hard look at this emerging trend, raising important questions about safety, regulation, and the growing gap between online promotion and clinical evidence.

What This Study Found

The review by Coutinho, De Oliveira Neves, and Camilo examined the current state of peptide use in both professional and recreational sport and bodybuilding settings. Researchers identified several categories of peptides that have gained popularity as performance-enhancing agents, including growth hormone secretagogues such as Ipamorelin, growth hormone-releasing hormone (GHRH) analogues such as CJC-1295 and Sermorelin, and synthetic peptide fragments such as Frag 176-191 and KPV.

According to the study, these compounds are primarily marketed for their purported benefits in muscle growth, fat metabolism, exercise recovery, and anti-inflammatory effects. Their pharmacological profiles — including enhanced receptor selectivity and improved molecular stability compared to naturally occurring hormones — have made them appealing both in legitimate medical research contexts and within bodybuilding communities.

However, the researchers found a critical disconnect between this popularity and the available evidence. The study suggests that most published clinical data on these peptides comes from therapeutic research conducted under controlled dosing regimens — conditions that bear little resemblance to the supraphysiological doses or stacked protocols commonly used in performance-enhancement settings. In other words, even where clinical studies do exist, they may not reflect the real-world risk profile faced by athletes and gym-goers who self-administer these compounds.

Emerging data highlighted in the review point to a range of potential adverse effects associated with peptide misuse, including cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability. The study characterizes these risks as incompletely understood, particularly in the context of long-term or combined use.

Clinical Significance

From a clinical standpoint, the review underscores a concerning pattern: substances with legitimate investigational value are being co-opted for off-label, unsupervised performance enhancement before their long-term safety profiles have been established. The researchers note that peptides represent a genuinely novel phase in the history of doping — one that differs meaningfully from the AAS era because these compounds are structurally similar to endogenous hormones, making them harder to detect and, in some cases, easier to rationalize as "natural."

The study suggests that this structural similarity to the body's own signaling molecules is precisely what makes peptides so pharmacologically interesting — and so clinically complex. Compounds like Sermorelin and CJC-1295 act on the same receptors as endogenous GHRH, which raises the possibility of disrupting normal hormonal feedback loops when used outside of a medically supervised context. The review emphasizes that the absence of long-term longitudinal safety data is one of the most significant gaps in the current literature.

For healthcare providers who may encounter patients using these substances, the study's findings serve as a reminder that peptide-related adverse events may not always be immediately attributable to these compounds, particularly given that many users do not disclose peptide use to their physicians. Clinicians are encouraged to ask specific questions about supplement and peptide use when evaluating unexplained metabolic, cardiovascular, or psychiatric symptoms in physically active patients.

Current Access and Compliance Context

One of the most troubling dimensions highlighted by this review is the largely unregulated supply chain through which most performance-enhancing peptides are obtained. The researchers note that products marketed online are frequently mislabeled or contaminated, meaning that users may not be consuming what they believe they are purchasing — introducing additional, unpredictable risk.

On the regulatory side, the World Anti-Doping Agency (WADA) has expanded its detection technologies in response to growing peptide misuse, yet the study suggests that significant analytical challenges remain. The structural similarity between synthetic peptides and endogenous hormones, combined with the relatively short half-lives of many of these compounds, makes reliable detection difficult — a gap that the researchers indicate has not yet been fully resolved.

Beyond elite competitive sport, the review draws attention to a largely unmeasured population: recreational gym-goers. Anecdotal reports and widespread promotion across social media platforms suggest growing uptake among fitness enthusiasts, including younger individuals. However, the study notes that formal prevalence data for this population are essentially absent, representing what the authors describe as a critical gap in current knowledge. Without reliable epidemiological data, it is difficult for public health agencies or regulatory bodies to mount a proportionate response.

What Patients Should Know

If you are considering or currently using peptide compounds for performance, body composition, or recovery purposes, the findings of this review carry several important implications:

• Clinical evidence is limited. The study suggests that the available research does not yet support the use of performance-enhancing peptides outside of medically supervised, investigational contexts. Claims circulating on social media and fitness forums frequently outpace what the science currently supports.
• Potential risks are real and not fully characterized. Researchers identified associations with cardiovascular strain, metabolic disruption, and psychiatric effects — but emphasize that long-term safety data simply do not exist yet for the doses and combinations used in performance settings.
• Product quality cannot be assumed. The unregulated market means there is no guarantee that what you purchase contains what it claims, at the dose it claims, without contamination.
• Your physician needs to know. If you are using or have used peptide compounds, disclosing this to your healthcare provider is essential for accurate diagnosis and safe care.

The review concludes that peptide use in both competitive and recreational settings should currently be considered high-risk and ethically problematic until longitudinal research clarifies safety and prevalence. This is not a condemnation of peptide science broadly — many of these compounds are subjects of legitimate ongoing research for conditions ranging from growth hormone deficiency to inflammatory disease. But that research must be conducted under appropriate clinical oversight, not replicated in home self-injection protocols based on forum recommendations.

Conclusion

The 2026 review by Coutinho and colleagues offers an important and timely synthesis of what is — and is not — known about peptide use in sport and fitness. The study suggests we are at an inflection point: peptides are already widely used, yet the evidence base to guide their safe application lags significantly behind their adoption. As this science continues to develop, working with a qualified, knowledgeable healthcare provider is the most responsible path forward for anyone interested in peptide therapies.

If you are seeking evidence-informed guidance on peptide therapies, the Peptide Association can connect you with a qualified medical professional in your area. Visit peptideassociation.org/find-a-doctor to find a doctor near you.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented is based on published research and is not a substitute for consultation with a licensed healthcare provider. Always speak with a qualified medical professional before starting, changing, or discontinuing any treatment or supplementation protocol.

---

Citation: Coutinho LFD, De Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026;66(6). doi:10.23736/S0022-4707.26.17773-1. PMID: 41880199.